Results 51 to 60 of about 17,271 (194)

Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis [PDF]

open access: yes, 2019
Abiraterone is an oral inhibitor of cytochrome P450 (17alpha)-hydroxylase/17,20 lyase (CYP17) complex critical to androgen production. Abiraterone in combination with prednisone is currently FDA approved for use in men with metastatic castration ...
Eryilmaz, Melek Karakurt   +2 more
core   +1 more source

Global Real‐World Outcomes of Olaparib in Metastatic Castration‐Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Evidence to guide the treatment for patients with metastatic castration‐resistant prostate cancer (mCRPC) and Homologous Recombination Repair (HRR) gene alterations outside of clinical trials remains limited. This was an observational, cohort study, including mCRPC patients with tumor harboring HRR alterations, progressed on a prior androgen ...
Lorena Incorvaia   +35 more
wiley   +1 more source

Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives

open access: yes, 2017
Joelle El-Amm,1 Rami Nassabein,1 Jeanny B Aragon-Ching2 1Division of Hematology and Oncology, Department of Internal Medicine, Lebanese American University, Beirut, Lebanon; 2GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA, USA Abstract ...
El-Amm J   +8 more
core   +1 more source

Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide

open access: yesBMC Research Notes, 2018
Objective The objective of this retrospective study was to evaluate whether the effect of second-line therapy of flutamide after bicalutamide can predict the response to abiraterone.
Yasushi Nakai   +5 more
doaj   +1 more source

Abirateron [PDF]

open access: yespharma-kritik, 2012
Abirateron kann in der Drittlinientherapie des metastasierenden Prostatakarzinoms verwendet werden. Es handelt sich um ein Pregnenolon-Derivat, das das Zytochrom CYP17A1 hemmt und so die Bildung von Testosteron-Vorstufen reduziert. Es ist in seiner Wirksamkeit bisher erst mit Placebo verglichen worden und vergleichsweise sehr teuer.
openaire   +1 more source

Bipolar Androgen Therapy as a Potential Mechanistic Bridge to Enhance PARP Inhibitor Efficacy in Prostate Cancer

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Prostate cancer remains a leading cause of cancer‐related mortality, largely driven by progression to metastatic castration‐resistant prostate cancer (mCRPC). Although poly(ADP‐ribose) polymerase inhibitors (PARPis) have improved outcomes in patients with homologous recombination repair (HRR) alterations, particularly in BRCA2‐mutated disease,
Jhen‐Hao Jhan   +4 more
wiley   +1 more source

Endocrine therapy‐induced cancer‐related fatigue in hormone‐dependent malignancies: Mechanisms, impact, and management strategies

open access: yesPrecision Medical Sciences, EarlyView.
Multipathway schematic of endocrine therapy–induced cancer‐related fatigue. Endocrine interventions trigger four interacting mechanisms—neuroendocrine dysregulation, systemic inflammation, energy‐metabolic failure, and psycho‐behavioral amplification—that culminate in the multidimensional CRF phenotype.
Jiajing Jiang   +7 more
wiley   +1 more source

Insulin‐Like Growth Factor Axis and Survival in Metastatic Hormone‐Sensitive Prostate Cancer: Post‐Hoc Analysis From the ENZAMET Phase 3 Trial

open access: yesThe Prostate, EarlyView.
ABSTRACT Background A higher ratio of IGF‐1:IGF binding protein 1 (IGFBP1) was associated with improved prognosis in the CHAARTED trial of docetaxel in participants with metastatic hormone‐sensitive prostate cancer (mHSPC). The ENZAMET trial demonstrated the survival benefit of adding enzalutamide to androgen deprivation therapy (ADT) in mHSPC, and ...
Michael A. Cilento   +15 more
wiley   +1 more source

Abiraterone and MDV3100 inhibits the proliferation and promotes the apoptosis of prostate cancer cells through mitophagy

open access: yesCancer Cell International, 2019
Background Abiraterone and MDV3100 are two effective anticancer agents for prostate cancer, however, the mechanism of their downstream action remains undefined.
Jingli Han   +12 more
doaj   +1 more source

Efficacy and safety of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials

open access: yesFrontiers in Oncology, 2023
BackgroundOlaparib has been proven for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This meta-analysis aims to comprehensively evaluate the efficacy and safety of the combination of olaparib and abiraterone in patients with ...
Zhanyang Luo   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy